Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

5-16 Cardiovascular Pharmacotherapeutics
mia BMJ 2:272, 1976.
396. Lloyd-Mostyn RH, Oram S: Modification by propranolol
of cardiovascular effects of induced hypoglycaemia.
Lancet 1:1213, 1975.
397. Fogari R, Zoppi A, Corradi L, et al: b Blocker effects
on plasma lipids during prolonged treatment
of hypertensive patients with hypercholesterolemia.
J Cardiovasc Pharmacol 33:534, 1999.
398. Dimmitt SB, Williams PD, Croft KD, Beilin LJ: Effects
of b-blockers on the concentration and oxidizability
of plasma lipids. Clin Sci 94:573, 1998.
399. Perez-Stable EJ, Halliday R, Gardiner PS, et al: The
effects of propranolol on cognitive function and
quality of life: a randomized trial among patients
with diastolic hypertension. Am J Med 108:359,
2000.
400. Jacob H, Brandt LJ, Farkas P, Frishman WH: Betaadrenergic
blockade and the gastrointestinal system.
Am J Med 74:1042, 1983.
401. Stephen SA: Unwanted effects of propranolol. Am J
Cardiol 18:463, 1966.
402. Lydakis C, Lip GYH, Beevers M, Beevers DG:
Atenolol and fetal growth in pregnancies complicated
by hypertension. Am J Hypertens 12:541,
1999.
403. Bailey R, Neale TJ: Rapid clonidine withdrawal
with blood pressure overshoot exaggerated by beta-blockade.
BMJ 1:942, 1976.
404. Agabiti-Rosei E, Brown JJ, Lever AF, et al: Treatment
of phaeochromocytoma and clonidine
withdrawal hypertension with labetalol. Br J Clin
Pharmacol 3(Suppl 3):809, 1976.
405. Wright P; Untoward effect associated with practolol
administration: oculomucocutaneous syndrome.
BMJ 1:595, 1975.
406. Blaufarb I, Pfeifer TM, Frishman WH: b Blockers:
drug interactions of clinical significance. Drug
Safety 13(6):359, 1995.
407. Opie LH, Frishman WH: Adverse cardiovascular
drug interactions and complications. In: Fuster
V, Alexander RW, O’Rourke RA, eds. Hurst’s The
Heart, 10th ed. New York: McGraw-Hill, 2001:2251.